171 related articles for article (PubMed ID: 30387871)
41. Study Protocol for Assessing the Efficacy of Compression Therapy Using Stockings and Sleeves to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients.
Yamanouchi K; Kuba S; Matsumoto M; Yano H; Morita M; Sakimura C; Otsubo R; Kanetaka K; Nagayasu T; Eguchi S
Acta Med Okayama; 2020 Oct; 74(5):455-459. PubMed ID: 33106704
[TBL] [Abstract][Full Text] [Related]
42. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
Chen CS; Zirpoli G; Barlow WE; Budd GT; McKiver B; Pusztai L; Hortobagyi GN; Albain KS; Damaj MI; Godwin AK; Thompson A; Henry NL; Ambrosone CB; Stringer KA; Hertz DL
J Natl Compr Canc Netw; 2023 Nov; 21(11):1172-1180.e3. PubMed ID: 37935109
[TBL] [Abstract][Full Text] [Related]
43. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
[TBL] [Abstract][Full Text] [Related]
44. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
Salgado TM; Quinn CS; Krumbach EK; Wenceslao I; Gonzalez M; Reed HL; Syverson JG; Etz RS; Vangipuram K; Barker MR; Henry NL; Farris KB; Hertz DL
Support Care Cancer; 2020 Sep; 28(9):4163-4172. PubMed ID: 31897779
[TBL] [Abstract][Full Text] [Related]
45. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Hsu Y; Sood AK; Sorosky JI
Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
[TBL] [Abstract][Full Text] [Related]
46. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
[TBL] [Abstract][Full Text] [Related]
47. Persistent weekly paclitaxel-induced peripheral neuropathy in early breast cancer patients enrolled in a randomized trial of cryotherapy.
Shigematsu H; Kimura Y; Itagaki T; Yasui D
Medicine (Baltimore); 2023 Apr; 102(16):e33580. PubMed ID: 37083796
[TBL] [Abstract][Full Text] [Related]
48. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Reeder-Hayes KE; Meyer AM; Hinton SP; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2017 Oct; 35(29):3298-3305. PubMed ID: 28727517
[TBL] [Abstract][Full Text] [Related]
49. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
Pignata S; De Placido S; Biamonte R; Scambia G; Di Vagno G; Colucci G; Febbraro A; Marinaccio M; Lombardi AV; Manzione L; Cartenì G; Nardi M; Danese S; Valerio MR; de Matteis A; Massidda B; Gasparini G; Di Maio M; Pisano C; Perrone F
BMC Cancer; 2006 Jan; 6():5. PubMed ID: 16398939
[TBL] [Abstract][Full Text] [Related]
50. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
[TBL] [Abstract][Full Text] [Related]
51. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
52. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort.
Shah A; Hoffman EM; Mauermann ML; Loprinzi CL; Windebank AJ; Klein CJ; Staff NP
J Neurol Neurosurg Psychiatry; 2018 Jun; 89(6):636-641. PubMed ID: 29439162
[TBL] [Abstract][Full Text] [Related]
53. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
[TBL] [Abstract][Full Text] [Related]
55. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Mehrotra S; Sharma MR; Gray E; Wu K; Barry WT; Hudis C; Winer EP; Lyss AP; Toppmeyer DL; Moreno-Aspitia A; Lad TE; Valasco M; Overmoyer B; Rugo H; Ratain MJ; Gobburu JV
AAPS J; 2017 Sep; 19(5):1411-1423. PubMed ID: 28620884
[TBL] [Abstract][Full Text] [Related]
56. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
[TBL] [Abstract][Full Text] [Related]
57. Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer.
Verhoeff-Jahja R; Ter Kuile MM; Weijl NI; Oosterkamp R; Cloos M; Portielje JEA; Kroep JR; Hinnen C
Support Care Cancer; 2022 Aug; 30(8):6947-6953. PubMed ID: 35543818
[TBL] [Abstract][Full Text] [Related]
58. Falls in persons with chemotherapy-induced peripheral neuropathy.
Tofthagen C; Overcash J; Kip K
Support Care Cancer; 2012 Mar; 20(3):583-9. PubMed ID: 21380613
[TBL] [Abstract][Full Text] [Related]
59. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
Rose PG; Smrekar M
Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
[TBL] [Abstract][Full Text] [Related]
60. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
Argyriou AA; Polychronopoulos P; Koutras A; Iconomou G; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
Support Care Cancer; 2006 Mar; 14(3):223-9. PubMed ID: 16021477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
